drugset / Trial / NCT06318481
TADCLOT- a Double Blind Randomized Controlled Trial
Phase 3
Completed
2200 enrolled
National Institute of Cardiovascular Diseases, Pakistan
PharmEvo Pvt Ltd · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.
Timeline
- Start
- 2024-02-19
- Primary completion
- 2025-02-20
- Completion
- 2025-02-20
Publications
- Hakeem A, Shah JA, Kumar R, Ali A, Lakho AA, Zeeshan H, Uddin MI, Khan K, Solangi B, Kumar M, Kumar M, Awan R, Ishaq H, Farooq F, Haq EU, Hameed A, Lehri WA, Zada S, Ali A, Raza A, Masood S, Humza A, Karim M; TADCLOT Investigators. Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial. J Am Coll Cardiol. 2025 Dec 9;86(23):2330-2345. doi: 10.1016/j.jacc.2025.08.041. Epub 2025 Aug 30.
- Hakeem A, Ali Shah J, Kumar R, Khan K, Zeeshan H, Lakho AA, Ali A, Uddin MI, Solangi B, Kumar M, Kumar M, Awan R, Dilawar F, Ishaq H, Farooq F, Ul Haq E, Hameed A, Lehri WA, Zada S, Raza A, Masood S, Humza A, Karim M. Rationale and design of the TADCLOT trial: A double blind randomized controlled trial comparing twice a day clopidogrel vs ticagrelor in reducing major cardiac events in patients with acute STEMI undergoing primary percutaneous coronary intervention. Am Heart J. 2025 Sep;287:141-150. doi: 10.1016/j.ahj.2025.03.021. Epub 2025 Apr 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |